- All doses were generally safe and well tolerated; and
- Individual immunologic and virologic responses were observed across cohorts at all dose levels.
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company's lead product candidate is HEPLISAV™, a Phase 3 investigational adult hepatitis B vaccine designed to enhance protection more rapidly and with fewer doses than current licensed vaccines. For more information, visit www.dynavax.com.
ISCOMATRIX® is a registered trademark of CSL Behring
Source: Dynavax Technologies